Eli Lilly and Company (NYSE:LLY) Given New $1,182.00 Price Target at Truist Financial

Eli Lilly and Company (NYSE:LLY) had its price objective increased by Truist Financial from $1,038.00 to $1,182.00 in a note issued to investors on Wednesday,MarketScreener reports. The firm presently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 13.59% from the company’s previous close.

A number of other analysts have also recently issued reports on the company. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. CICC Research boosted their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,027.95.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,040.55 on Wednesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a 50 day simple moving average of $838.20 and a 200 day simple moving average of $782.36. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,040.72. The firm has a market cap of $983.72 billion, a P/E ratio of 68.11, a P/E/G ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the business posted $1.18 earnings per share. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in Eli Lilly and Company during the third quarter worth approximately $1,489,000. Silvant Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 16.8% during the third quarter. Silvant Capital Management LLC now owns 110,064 shares of the company’s stock worth $83,979,000 after buying an additional 15,796 shares during the last quarter. Advisory Services Network LLC lifted its holdings in shares of Eli Lilly and Company by 4.9% during the 3rd quarter. Advisory Services Network LLC now owns 50,933 shares of the company’s stock worth $38,862,000 after acquiring an additional 2,370 shares during the period. Kozak & Associates Inc. increased its position in shares of Eli Lilly and Company by 140.0% during the 3rd quarter. Kozak & Associates Inc. now owns 60 shares of the company’s stock worth $46,000 after purchasing an additional 35 shares in the last quarter. Finally, San Luis Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 111.3% during the third quarter. San Luis Wealth Advisors LLC now owns 1,084 shares of the company’s stock worth $827,000 after purchasing an additional 571 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.